Research ArticleClinical Studies

Relationship Between Daily Dose of Everolimus and Treatment Effect in Patients With Luminal HER2-negative Metastatic Breast Cancer

YUMIKO USHIYAMA, YOSHIYA HORIMOTO, FUMI MURAKAMI, YUMIKO ISHIZUKA, MISATO OKAZAKI and JUNICHIRO WATANABE
Anticancer Research November 2023, 43 (11) 5253-5259; DOI: https://doi.org/10.21873/anticanres.16727

Article Information

vol. 43 no. 11 5253-5259
DOI 
https://doi.org/10.21873/anticanres.16727
PubMed 
37909948
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received August 29, 2023
  • Revision received September 18, 2023
  • Accepted September 19, 2023
  • Published online November 1, 2023.
Copyright & Usage 
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. YUMIKO USHIYAMA1,
  2. YOSHIYA HORIMOTO1,2⇑,
  3. FUMI MURAKAMI1,3,
  4. YUMIKO ISHIZUKA1,
  5. MISATO OKAZAKI1 and
  6. JUNICHIRO WATANABE1
  1. 1Department of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan;
  2. 2Department of Breast Oncology and Surgery, Tokyo Medical University, Tokyo, Japan;
  3. 3Department of General Surgery, Juntendo University Nerima Hospital, Tokyo, Japan
  1. Correspondence to: Yoshiya Horimoto, Department of Breast Oncology, Juntendo University, Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Tel: +81 338133111, e-mail: horimoto{at}juntendo.ac.jp
View Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Relationship Between Daily Dose of Everolimus and Treatment Effect in Patients With Luminal HER2-negative Metastatic Breast Cancer
YUMIKO USHIYAMA, YOSHIYA HORIMOTO, FUMI MURAKAMI, YUMIKO ISHIZUKA, MISATO OKAZAKI, JUNICHIRO WATANABE
Anticancer Research Nov 2023, 43 (11) 5253-5259; DOI: 10.21873/anticanres.16727
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords